Chris Jacobs sold Biogen Inc (NASDAQ: BIIB)
Chris Jacobs (R-NY), a U.S. Representative, has disclosed 1 trade in Biogen Inc (BIIB) since 2021, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Chris Jacobs sold $1,001 - $15,000 of Biogen Inc (NASDAQ: BIIB) on January 4, 2021. Since that trade, BIIB is down -13.88% against the S&P 500 up +112.48%, an outperformance of -126.36%.
Data updated
Chris Jacobs's BIIB trades vs the price
BIIB is down -13.88% since Chris Jacobs sold on January 4, 2021, versus +112.48% for the S&P 500.
Performance since this trade
All Chris Jacobs BIIB trades
Chris Jacobs & BIIB trading FAQ
Is it legal for Chris Jacobs to trade Biogen Inc (BIIB) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Biogen Inc (BIIB), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Chris Jacobs sell BIIB?
Chris Jacobs disclosed a sale of $1,001 - $15,000 of Biogen Inc (BIIB) on January 4, 2021, according to public STOCK Act filings.
How has BIIB performed since Chris Jacobs's trade?
Since Chris Jacobs sold BIIB on January 4, 2021, the stock is down -13.88%, versus +112.48% for the S&P 500 over the same period, an outperformance of -126.36%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BIIB trades?
Quantellect tracks every disclosed congressional trade in Biogen Inc (BIIB) on the Biogen Inc congressional trading page, which aggregates filings across all members of Congress.
Chris Jacobs's BIIB tradesAll congressional filings for Biogen IncChris Jacobs's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.